Icariin: Multi‑target natural products for the multi‑stage prevention and treatment of breast cancer (Review)
Molecular and Clinical Oncology · 06.05.2026 · 25 (1) · 1-8
DOI: 10.3892/mco.2026.2954 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular and Clinical Oncology, online erschienen am 06.05.2026. Verfasst von Yu Wen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Hospital Traditional Chinese Medicine of Xiamen, Xiamen, Fujian 361009, P.R. China. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The present review examines the intricate relationship between icariin and breast cancer (BC), encompassing foundational theoretical concepts, epidemiological data, diagnostic methodologies, therapeutic approaches, ongoing debates and prospective future developments. The foundational theoretical concepts address the mechanisms through which icariin influences BC pathogenesis, as well as its pharmacokinetic and pharmacodynamic properties and historical context. The epidemiological section analyzes the global incidence and prevalence of BC, alongside its underlying pathophysiology. Diagnostic methodologies are discussed with a focus on imaging technologies, biomarkers, and the innovative role of icariin in advancing diagnostic techniques. Therapeutic approaches investigate icariin's potential as a chemo-preventive agent, its synergistic interactions with conventional therapies and the outcomes of clinical trials. The section on controversies explores discussions surrounding icariin's efficacy, safety and the associated regulatory and ethical considerations. Future directions emphasize emerging trends, the potential for personalized medicine, and future prospects in BC treatment. The present review aims to offer a comprehensive understanding of icariin's role in BC research and therapeutic applications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Hospital Traditional Chinese Medicine of Xiamen, Xiamen, Fujian 361009, P.R. China.
- Xiamen Key Laboratory for Research and Transformation of Traditional Chinese Medicine Formulations, Xiamen, Fujian 361009, P.R. China.
- Drug Clinical Trial Institution Office, Hospital Traditional Chinese Medicine of Xiamen, Xiamen, Fujian 361009, P.R. China.
Zitieren
APA
Wen, Y., Chen, Y., Yang, L., Wu, T., Peng, Q., Xie, H., & Chen, X. (2026). Icariin: Multi‑target natural products for the multi‑stage prevention and treatment of breast cancer (Review). Molecular and Clinical Oncology, 25(1), 1-8. https://doi.org/10.3892/mco.2026.2954
Vancouver
Wen Y, Chen Y, Yang L, Wu T, Peng Q, Xie H, et al. Icariin: Multi‑target natural products for the multi‑stage prevention and treatment of breast cancer (Review). Molecular and Clinical Oncology. 2026;25(1):1-8. doi:10.3892/mco.2026.2954
BibTeX
@article{Wen2026,
author = {Wen, Yu and Chen, Yunyan and Yang, Lei and Wu, Tingfen and Peng, Qinghua and Xie, Huiyan and Chen, Xuemei},
title = {Icariin: Multi‑target natural products for the multi‑stage prevention and treatment of breast cancer (Review)},
journal = {Molecular and Clinical Oncology},
year = {2026},
volume = {25},
number = {1},
pages = {1--8},
doi = {10.3892/mco.2026.2954}
}
EUVIMED